April 18, 2016 8:31 AM | 1 min read |
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Shares of
Medivation Inc (NASDAQ: MDVN) were trading higher by more than 3 percent early Monday following reports the company is being eyed as an acquisition target by more than 1 potential buyer.Medivation has already received interest from
Sanofi SA (ADR) (NYSE: SNY) and analysts suggested the stock could be worth $54 to $59 per share in terms of operational synergies and $60 to $75 per share with leveraged tax benefits.Related Link:
Medivation Surges On Reported Pushback Of Sanofi Takeover EffortAccording to UK-based
The Times, AstraZeneca plc (ADR) (NYSE: AZN) has been exploring an acquisition of Medivation for the past 6 months. The publication, citing "City [London's financial center] and Wall Street sources," added that while AstraZeneca hasn't made an official bid, management is "looking very closely."AstraZeneca's stock showed no trades early Monday morning.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.